(NASDAQ: BRNS) Barinthus Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 17.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 23.64%.
Barinthus Biotherapeutics's earnings in 2025 is -$61,074,000.On average, 2 Wall Street analysts forecast BRNS's earnings for 2025 to be -$54,054,789, with the lowest BRNS earnings forecast at -$61,315,880, and the highest BRNS earnings forecast at -$46,793,698. On average, 1 Wall Street analyst forecast BRNS's earnings for 2026 to be -$68,576,972, with the lowest BRNS earnings forecast at -$68,576,972, and the highest BRNS earnings forecast at -$68,576,972.
In 2027, BRNS is forecast to generate -$80,275,396 in earnings, with the lowest earnings forecast at -$80,275,396 and the highest earnings forecast at -$80,275,396.